Viracta Therapeutics

Viracta Therapeutics

Viracta Therapeutics

Viracta is advancing medicines based on its viral gene activation therapy approach to benefit patients with viral-associated cancers & other serious diseases.
Raised
$18.4M
Follow us
Alexa global traffic share
Twitter followers
Latest funding
Team Size
2
Employees
FinSMEs

Viracta Therapeutics Closes Series D Financing

$18,400,000 Venture capital (Series B)
FierceBiotech

Viracta nabs $18.4M, Soon-Shiong as vice chair in Series B